CD33 and acute myeloid leukemia: Mylotarg (Gemtuzumab ozogamicin; GO) is a humanized anti-CD33 monoclonal antibody drug conjugated with calicheamicin derivative and is the only FDA-approved antibody for use in CD33-positive AML [115].